CA3182814A1 - Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof - Google Patents

Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Info

Publication number
CA3182814A1
CA3182814A1 CA3182814A CA3182814A CA3182814A1 CA 3182814 A1 CA3182814 A1 CA 3182814A1 CA 3182814 A CA3182814 A CA 3182814A CA 3182814 A CA3182814 A CA 3182814A CA 3182814 A1 CA3182814 A1 CA 3182814A1
Authority
CA
Canada
Prior art keywords
cells
macrophages
agent
myeloid cells
vsig4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3182814A
Other languages
English (en)
French (fr)
Inventor
Elizabeth CULYBA
Phuong Anh Nguyen
Maja RAZLOG
Tatiana I. NOVOBRANTSEVA
Igor Feldman
Stephen L. SAZINSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verseau Therapeutics Inc
Original Assignee
Verseau Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseau Therapeutics Inc filed Critical Verseau Therapeutics Inc
Publication of CA3182814A1 publication Critical patent/CA3182814A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
CA3182814A 2020-05-29 2021-05-28 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof Pending CA3182814A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032337P 2020-05-29 2020-05-29
US63/032,337 2020-05-29
PCT/US2021/034784 WO2021243169A1 (en) 2020-05-29 2021-05-28 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (1)

Publication Number Publication Date
CA3182814A1 true CA3182814A1 (en) 2021-12-02

Family

ID=78722851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3182814A Pending CA3182814A1 (en) 2020-05-29 2021-05-28 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Country Status (11)

Country Link
US (1) US20230348603A1 (enExample)
EP (1) EP4157886A4 (enExample)
JP (1) JP2023527410A (enExample)
KR (1) KR20230017778A (enExample)
CN (1) CN115996953A (enExample)
AU (1) AU2021281356A1 (enExample)
BR (1) BR112022023892A2 (enExample)
CA (1) CA3182814A1 (enExample)
IL (1) IL298545A (enExample)
TW (1) TW202210523A (enExample)
WO (1) WO2021243169A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240392037A1 (en) * 2022-01-10 2024-11-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to neutrophil elastase polypeptides
KR20240058017A (ko) * 2022-10-21 2024-05-03 주식회사 유틸렉스 항-vsig4 항체를 포함하는 항암용 조성물
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
JP2025027841A (ja) * 2023-08-17 2025-02-28 国立大学法人 東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
KR20250062590A (ko) * 2023-10-31 2025-05-08 인제대학교 산학협력단 신장 이식 후 만성거부반응 진단용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130204A1 (en) * 2007-04-24 2008-10-30 Eucell Bio Co., Ltd. New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof
AU2009319864A1 (en) * 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
CN102459335B (zh) * 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
KR101730868B1 (ko) * 2013-09-13 2017-04-27 인제대학교 산학협력단 Ｖｓｉｇ４ 억제제를 유효성분으로 포함하는 난소암 예방 또는 치료용 약학조성물
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
CN110944666B (zh) * 2017-06-26 2024-12-31 博奥泰克尼公司 杂交瘤克隆、vsig-4的单克隆抗体，以及制备和使用的方法
MX2021003673A (es) * 2018-09-28 2021-09-23 Eutilex Co Ltd Anticuerpos anti-vsig4 humano y usos de los mismos.

Also Published As

Publication number Publication date
EP4157886A4 (en) 2024-10-16
TW202210523A (zh) 2022-03-16
WO2021243169A1 (en) 2021-12-02
EP4157886A1 (en) 2023-04-05
IL298545A (en) 2023-01-01
BR112022023892A2 (pt) 2022-12-27
AU2021281356A1 (en) 2023-01-19
CN115996953A (zh) 2023-04-21
KR20230017778A (ko) 2023-02-06
JP2023527410A (ja) 2023-06-28
US20230348603A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US12552873B2 (en) Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20220396627A1 (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20230348603A1 (en) Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
AU2019293600A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
US20220251233A1 (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20220363752A1 (en) Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241113

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250527

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250527

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250527

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250812

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250812

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250812

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250812

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250812

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251202